Applied Research on a Non-pharmacological Intervention Program for Older Adults With Subjective Cognitive Decline
1 giugno 2026 aggiornato da: Zhi Cai, China Medical University, China
Applied Research on a Group-based Non-pharmacological Intervention Program for Community-dwelling Older Adults With Subjective Cognitive Decline
This study aims to verify the short-term and long-term effects of a group-based non-pharmacological intervention program for community-dwelling older adults with subjective cognitive decline, and to evaluate its implementation outcomes, through a rigorously designed cluster randomized controlled trial.
Panoramica dello studio
Stato
Non ancora reclutamento
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This study adopts a cluster randomized controlled design to implement a group-based non-pharmacological intervention for older adults with subjective cognitive decline.
The effects of the intervention on global cognitive function, episodic memory, executive function, attention, language function, subjective memory function, anxiety, depression, social participation, gait speed, physical activity level, and healthy lifestyle behaviors will be evaluated.
In addition, implementation outcomes will be assessed based on the RE-AIM framework and the CFIR framework.
Tipo di studio
Interventistico
Iscrizione (Stimato)
218
Fase
- Non applicabile
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
No
Descrizione
Inclusion Criteria Aged ≥60 Community dwelling Subjective memory decline, confirmed by Subjective Cognitive Decline Questionnaire(SCD-Q9)≥5 Montreal Cognitive Assessment (MoCA) scores ≥19, 22, or 24 for participants who had primary school, middle school, or higher education, respectively Overall intact activities of daily living No planned exercise or cognitive intervention activities within the past six months Voluntary participants who will be informed of the study objectives by the researcher and will sign the informed consent form.
Exclusion Criteria Any other neurodegenerative diseases (such as mild cognitive impairment, dementia, Parkinson's disease, stroke, etc.) Any severe or unstable internal medical conditions (i.e., unstable or severe asthma or heart disease, liver and kidney diseases, uncontrolled hypertension, severe metabolic diseases, etc.) Severe depressive, anxiety or other psychiatric disorders Movement contraindications Those currently participating in other research trials.
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Non-Pharmacological Interventions
|
6 components(social intercourse, cognitive interventions, physical activities interventions, rational diet, understanding and risk management of diseases, emotion management)
|
|
Altro: Waiting List Control Group
To ensure ethical fairness, the same intervention program will subsequently be provided to the waitlist control group after positive effects are confirmed in the intervention group.
|
To ensure ethical fairness, the same intervention program will subsequently be provided to the waitlist control group after positive effects are confirmed in the intervention group.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Episodic memory
Lasso di tempo: week0，week12，week24
|
Using the Huashan version of the Auditory Verbal Learning Test (AVLT) for assessment, it is mainly used to evaluate immediate recall, short-delay recall, long-delay recall, and other key components.
The test includes 12 words belonging to three semantic categories (4 words per category).
The testing procedure is as follows: The examiner reads out the 12 words in sequence, and the subject immediately recalls them.
This process is repeated three consecutive times to form the immediate memory test.
After an interval of 5 minutes, short-delay recall is conducted, and after 20 minutes, long-delay recall is implemented.
The scoring rule is that each correctly recalled word earns 1 point.
The immediate memory score is the sum of correct recalls from the first three trials (maximum score 36).
This study records the scores for immediate recall, short-delay recall, and long-delay recall, with higher scores indicating better memory function.
|
week0，week12，week24
|
|
Gobal cognitive function
Lasso di tempo: week0，week12，week24
|
The assessment uses the Montreal Cognitive Assessment (MoCA).
Higher scores indicate better performance, with a minimum score of 0 and a maximum score of 30.
|
week0，week12，week24
|
|
Executive function
Lasso di tempo: week0，week12，week24
|
The Shape Trail Test (STT) was used to assess executive function.
The test consists of two parts: Part A requires participants to connect 25 numbers in ascending order; Part B involves 25 numbers presented within two different shapes.
The scoring indicators are the time taken to complete STT-A and STT-B, with shorter completion times indicating better executive function.
|
week0，week12，week24
|
|
Attention
Lasso di tempo: week0，week12，week24
|
The Digit Symbol Substitution Test (DSST) is used to assess the patient's attention.
The subject is required to match the corresponding symbols to the numbers (1-9) as quickly as possible within 90 seconds.
Each correctly filled symbol earns 1 point, and a reversed symbol earns 0.5 points.
The maximum score for the test is 90.
|
week0，week12，week24
|
|
Linguistic function
Lasso di tempo: week0，weel12，week24
|
Animal verbal fluency is used to assess a patient's language fluency.
The test requires the subject to name as many examples as possible within the category of animals in one minute.
Scoring is typically based on the total number of correctly named animal names.
Lower scores indicate reduced language ability.
|
week0，weel12，week24
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Depression
Lasso di tempo: week0，weel12，week24
|
The short version of the Geriatric Depression Scale (Geriatric Depression Scale-15, GDS-15) is used for assessment.
The total score ranges from 0 to 15, and the score is positively correlated with the severity of depression.
|
week0，weel12，week24
|
|
Anxiety
Lasso di tempo: week0，week12，week24
|
The Geriatric Anxiety Inventory-20 (GAI-20) is used for assessment.
This scale consists of 20 items, and respondents answer based on their emotional feelings over the past week.
A response of "Yes" is scored as 1 point, while "No" is scored as 0 points.
The total score ranges from 0 to 20, with higher scores indicating more severe anxiety.
|
week0，week12，week24
|
|
Social network
Lasso di tempo: week0，week12，week24
|
The Lubben Social Network Scale-6 (LSNS-6) is a short version of the Lubben Social Network Scale.
It is primarily used to measure an individual's level of social connectedness in two dimensions: family relationships and peer interactions.
The scale consists of six assessment items and uses a graded scoring system: 0 points indicate no such social members, 1 point corresponds to 1 person, 2 points to 2 people, 3 points to 3-4 people, 4 points to 5-8 people, and 5 points applies to groups of 9 or more individuals.
Lower scores indicate poorer levels of social network connectedness.
|
week0，week12，week24
|
|
Social participation
Lasso di tempo: week0，week12，week24
|
This study employed the Social Participation Level Assessment Tool revised by Wei Xiuping, which was developed based on national health survey data of the elderly population.
The measurement tool comprises two main dimensions: cultural organization participation and family/personal affairs, encompassing a total of 10 specific items.
A five-point Likert scale was used for measurement, and the total score is positively correlated with the level of social participation-that is, a higher score indicates a more significant degree of social participation among the respondents.
|
week0，week12，week24
|
|
Timed "Up and Go" test
Lasso di tempo: week0，week12，week24
|
During the test, the participant sits on a chair with armrests and a backrest.
Upon hearing the instruction, they stand up, walk 3 meters forward at their usual gait, then turn around, return to the chair, and sit down.
The average of two test trials is recorded.
|
week0，week12，week24
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Stimato)
30 giugno 2026
Completamento primario (Stimato)
30 giugno 2029
Completamento dello studio (Stimato)
1 dicembre 2029
Date di iscrizione allo studio
Primo inviato
20 maggio 2026
Primo inviato che soddisfa i criteri di controllo qualità
1 giugno 2026
Primo Inserito (Effettivo)
5 giugno 2026
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
5 giugno 2026
Ultimo aggiornamento inviato che soddisfa i criteri QC
1 giugno 2026
Ultimo verificato
1 giugno 2026
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 【2026】161
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
NO
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .